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Background: Existing risk stratification tools have limitations and clinical experience suggests they are
not used routinely. The aim of this study was to develop and validate a preoperative risk stratification tool
to predict 30-day mortality after non-cardiac surgery in adults by analysis of data from the observational
National Confidential Enquiry into Patient Outcome and Death (NCEPOD) Knowing the Risk study.
Methods: The data set was split into derivation and validation cohorts. Logistic regression was used to
construct a model in the derivation cohort to create the Surgical Outcome Risk Tool (SORT), which was
tested in the validation cohort.
Results: Prospective data for 19097 cases in 326 hospitals were obtained from the NCEPOD study.
Following exclusion of 2309, details of 16788 patients were analysed (derivation cohort 11219, validation
cohort 5569). A model of 45 risk factors was refined on repeated regression analyses to develop a
model comprising six variables: American Society of Anesthesiologists Physical Status (ASA-PS) grade,
urgency of surgery (expedited, urgent, immediate), high-risk surgical specialty (gastrointestinal, thoracic,
vascular), surgical severity (from minor to complex major), cancer and age 65years or over. In the
validation cohort, the SORT was well calibrated and demonstrated better discrimination than the ASA-PS
and Surgical Risk Scale; areas under the receiver operating characteristic (ROC) curve were 0⋅91 (95 per
cent c.i. 0⋅88 to 0⋅94), 0⋅87 (0⋅84 to 0⋅91) and 0⋅88 (0⋅84 to 0⋅92) respectively (P <0⋅001).
Conclusion: The SORT allows rapid and simple data entry of six preoperative variables, and provides a
percentage mortality risk for individuals undergoing surgery.
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Introduction
Approximately8millionsurgicalproceduresareperformed
in the UK each year, and 230 million worldwide1. Accurate
risk stratification facilitates meaningful informed patient
consent and shared decision-making. It might also iden-
tify high-risk patients who could benefit from targeted
interventions including goal-directed fluid therapy2, post-
operative respiratory support3 and admission to critical
care4. There is some evidence that appropriately tar-
getedinterventions5 canreducemortality6,7,morbidityand
length of hospital stay8.
Clinical judgement alone is not a reliable predictor
of adverse outcome9. Thus a variety of risk assessment
tools have been developed to help clinicians calculate
perioperative risk10 that complement investigations for
identifying high-risk patients, such as cardiopulmonary
exercise testing11,12 and biomarker assays13. Exercise
testing facilities are not available routinely14,15 and are
inappropriate in urgent or emergency surgical patients.
The potential value of biomarkers such as N-terminal
pro-B-type natriuretic peptide is still emerging16–18.
Risk stratification tools remain the most readily and
widely available means of determining perioperative
risk.
Some risk stratification tools consist entirely of pre-
operative variables, such as the American Society of
Anesthesiologists Physical Status (ASA-PS) grade19 and
the Surgical Risk Scale (SRS)20. Other tools combine
preoperative data with intraoperative/postoperative vari-
ables, such as the Physiological and Operative Severity
Score for the enUmeration of Mortality and morbidity
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Case report forms collected in
Knowing the Risk study n = 19 097
Excluded based on exclusion criteria n = 262 (1·4%)
    Aged < 16 years n = 8
    Duplicate n = 120
    Specialty not surgical n = 102
    Operation date outside study interval n = 32
Excluded owing to missing data n = 2047
patients (10·7% of original data set)
    Mortality status n = 916
    Age n = 7
    ASA-PS grade n = 367
    Operative urgency n = 381
    Surgical severity n = 74
    Operation date n = 86
    Surgical specialty n = 216
Eligible patients n = 18 835
Included in analysis n = 16 788
Fig. 1 Reasons for exclusion from the study. ASA-PS, American Society of Anesthesiologists Physical Status
(POSSUM)21, and the subsequent Portsmouth version
(P-POSSUM)22. Clinical experience suggests that their
incorporation into clinical practice is variable. Reluctance
to use them may relate to concerns over the accuracy,
complexity23 and/or accessibility of data, for example if
a blood test is required. A recent systematic review23 of
risk stratification tools validated in heterogeneous patient
cohorts found that P-POSSUM and the SRS were the
most widely validated and accurate risk stratification tools
available. However, both have their limitations. Overall,
clinical experience suggests that existing risk stratification
tools are not widely used in the UK or elsewhere.
In 2011, the National Confidential Enquiry into Patient
Outcome and Death (NCEPOD) published Knowing the
Risk, a report assessing perioperative care14. Key recom-
mendations included the introduction of a national system
to identify patients at high risk of morbidity and death
after surgery; and that a mortality risk assessment should
be made explicit to patients before surgery, and docu-
mented on the consent form. It was also recommended
that high-risk patients be identified before operation to
aid planning and provision of critical care resources. An
important step towards meeting these recommendations
wouldbeachievedbyariskstratificationtoolthatconsisted
entirely of readily available preoperative variables which
enabled easy calculation of a predicted percentage mortal-
ity.Thus,aposthocanalysisofdatacollectedintheKnowing
the Risk study was conducted, to develop and validate a risk
stratification tool that met these requirements, and com-
pare it with existing preoperative risk stratification tools.
Methods
The Knowing the Risk study was a prospective, multi-
centre, observational cohort study. The initial data collec-
tion was undertaken for 7days from midnight on 1 March
until midnight on 8 March 2010. National Health Service
(NHS) hospitals in England, Wales and Northern Ireland,
public hospitals in the Isle of Man, Guernsey and Jersey,
and independent-sector hospitals in all these regions, were
invited to participate. Perioperative data were collected on
paper forms by anaesthetists at the time of surgery. Details
of the study design and data collection methodology have
been described previously14 and an extract of the form can
be found in Appendix S1 (supporting information). Data
were collected without obtaining patient consent or ethical
approval as the study was not defined as research under the
Health Research Authority (formerly National Research
Ethics Service). However, Section 251 approval had been
obtained from the Health Research Authority Confiden-
tiality Advisory Group (formerly the National Informa-
tion Governance Board, NIGB) to collect identifiable data
without consent. For the work described here, further
NIGB approval was obtained to extend the data-holding
interval for England and Wales. Data Access Agreements
were drawn up for each Northern Ireland Trust during
the Knowing the Risk study. Approval was subsequently
obtained from the Privacy Advisory Committee for North-
ern Ireland to extend the data-holding interval.
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Table 1 Descriptive data for patients excluded for missing
mortality status in comparison with the whole data set
Mortality data
missing
(n=916)
Mortality data
known
(n=16788)
Mean age (years) 60⋅55 5 ⋅8
Missing data 59 (6⋅4) –
Sex ratio (M:F) 428:488 7481:9307
ASA-PS grade
I 253 (27⋅6) 5416 (32⋅3)
II 370 (40⋅4) 7585 (45⋅2)
III 179 (19⋅5) 3339 (19⋅9)
IV 28 (3⋅1) 417 (2⋅5)
V1 ( 0 ⋅1) 31 (0⋅2)
Missing data 85 (9⋅3) –
Urgency of surgery
Elective 569 (62⋅1) 10987 (65⋅4)
Expedited 95 (10⋅4) 2136 (12⋅7)
Urgent 176 (19⋅2) 3424 (20⋅4)
Immediate 8 (0⋅9) 241 (1⋅4)
Missing data 68 (7⋅4) –
Severity
Minor 72 (7⋅9) 1423 (8⋅5)
Intermediate 188 (20⋅5) 4134 (24⋅6)
Major 281 (30⋅7) 5488 (32⋅7)
Xmajor/complex 299 (32⋅6) 5743 (34⋅2)
Missing data 76 (8⋅3) –
Co-morbidities
None documented 551 (60⋅2) 9472 (56⋅4)
Arrhythmia 85 (9⋅3) 1177 (7⋅0)
Cancer 84 (9⋅2) 1649 (9⋅8)
Cirrhosis 10 (1⋅1) 123 (0⋅7)
Congestive cardiac failure 26 (2⋅8) 276 (1⋅6)
Smoker 71 (7⋅8) 1689 (10⋅1)
Diabetes (insulin-dependent) 15 (1⋅6) 445 (2⋅7)
Diabetes (non-insulin-dependent) 58 (6⋅3) 1128 (6⋅7)
Ischaemic heart disease 99 (10⋅8) 1635 (9⋅7)
Respiratory disease 109 (11⋅9) 2082 (12⋅4)
TIA/stroke 34 (3⋅7) 677 (4⋅0)
Values in parentheses are percentages. ASA-PS, American Society of
Anesthesiologists Physical Status; Xmajor, extra major; TIA, transient
ischaemic attack.
Inclusion/exclusion criteria
Data were analysed for patients aged 16years or over who
underwent surgery of any urgency (immediate, urgent,
expedited or elective) and required a planned overnight
admission. Surgery was defined as a procedure performed
in an operating theatre by a surgeon. Patients undergoing
day-case surgery, obstetric procedures, neurosurgery, car-
diac or transplant surgery were excluded. If a patient had
more than one procedure during the study interval, data
for the most complex procedure were used. Patients were
excluded if any of the following key variables were missing:
age/date of birth, operative procedure or urgency, opera-
tion date and surgical severity, ASA-PS grade and mortality
status.
Data set
In the prospectively collected Knowing the Risk data set,
the surgical procedure was described using free text. In
the analysis described below, data coders used this to cat-
egorize each procedure according to surgical type (for
exampleabdominal – gastrointestinal)andseverity.Where
the free-text surgical procedure was missing, the opera-
tion was identified from OPCS coding obtained retrospec-
tively using patient identifiers provided during the initial
study.Severitycodingintofourcategories(minor,interme-
diate, major or extra major (Xmajor)/complex) was based
on the reference manual for the AXA Specialist Procedure
Codes24, which is used to grade the magnitude of surgical
procedures in UK independent hospitals. A comparison of
the surgical severity for all orthopaedic and gastrointesti-
nal surgical procedures (the two most common surgical
specialty groups in the study sample) was made to assess
similarities between the AXA and British United Provident
Association (BUPA) coding schedules, as the BUPA sched-
ule has been used in previous studies20. Clinical judgement
was used for procedures falling under more than one sur-
gical type, and where there was no listing for a procedure
in the AXA schedule. Two clinical reviewers reached agree-
ment on how to classify such procedures.
Data on deaths within 30days were provided retrospec-
tively by each hospital. In addition, following publication
of the Knowing the Risk report, further data cleaning and
collection were undertaken to complete missing data. Data
linkage with the Office for National Statistics (ONS) (for
England and Wales) and the Northern Ireland Statistics
and Research Agency (NISRA) was used to validate dates
of deaths and provide further mortality data. The final data
linkage exercisestookplaceon8February2013(ONS)and
26 March 2013 (NISRA), approximately 3years after the
initial data collection.
Statistical analysis
Univariable analyses were performed initially using χ2 test-
ing to assess the relationship between each independent
variableand30-daymortality.Variablesthatwerenotavail-
able for more than 10 per cent of patients were omitted
from the analyses. In addition, 44⋅7 per cent of height and
31⋅7 per cent of weight data were estimated, so body mass
index was not entered as a variable owing to the likelihood
of inaccurate estimates25.
Subsequently, the data set was divided randomly into two
cohorts: a derivation cohort of approximately two-thirds
of the sample, and a validation cohort consisting of the
remainder, as described previously26,27. Logistic regression
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Table 2 Descriptive data for the study, including 30-day mortality
Derivation cohort Validation cohort Whole data set
No. of patients Mortality (%) No. of patients Mortality (%) No. of patients Mortality (%)
All patients 11219 (100) 1⋅3 5569 (100) 1⋅6 16788 (100) 1⋅4
Age (years)
<65 6989 (62⋅3) 0⋅4 3506 (63⋅0) 0⋅7 10495 (62⋅5) 0⋅5
≥65 and<80 3073 (27⋅4) 1⋅6 1495 (26⋅8) 1⋅5 4568 (27⋅2) 1⋅6
≥ 80 1157 (10⋅3) 6⋅1 568 (10⋅2) 7⋅0 1725 (10⋅3) 6⋅4
ASA-PS grade
I 3616 (32⋅2) 0⋅1 1800 (32⋅3) 0⋅0 5416 (32⋅3) 0⋅0
II 5108 (45⋅5) 0⋅5 2477 (44⋅5) 0⋅5 7585 (45⋅2) 0⋅5
III 2190 (19⋅5) 3⋅1 1149 (20⋅6) 3⋅5 3339 (19⋅9) 3⋅2
IV 286 (2⋅5) 14⋅7 131 (2⋅4) 20⋅6 417 (2⋅5) 16⋅5
V1 9 ( 0 ⋅2) 63 12 (0⋅2) 58 31 (0⋅2) 61
Urgency of surgery
Elective 7374 (65⋅7) 0⋅3 3613 (64⋅9) 0⋅4 10987 (65⋅4) 0⋅3
Expedited 1415 (12⋅6) 2⋅1 721 (12⋅9) 1⋅4 2136 (12⋅7) 1⋅9
Urgent 2282 (20⋅3) 3⋅2 1142 (20⋅5) 4⋅6 3424 (20⋅4) 3⋅7
Immediate 148 (1⋅3) 15⋅59 3 ( 1 ⋅7) 11 241 (1⋅4) 13⋅7
Severity
Minor 935 (8⋅3) 0⋅7 488 (8⋅8) 1⋅0 1423 (8⋅5) 0⋅8
Intermediate 2743 (24⋅4) 0⋅8 1391 (25⋅0) 0⋅7 4134 (24⋅6) 0⋅8
Major 3680 (32⋅8) 1⋅1 1808 (32⋅5) 1⋅4 5488 (32⋅7) 1⋅2
Xmajor/complex 3861 (34⋅4) 2⋅0 1882 (33⋅8) 2⋅4 5743 (34⋅2) 2⋅1
Co-morbidities
None documented 6363 (56⋅7) 0⋅3 3109 (55⋅8) 0⋅4 9472 (56⋅4) 0⋅3
Arrhythmia 795 (7⋅1) 5⋅7 382 (6⋅9) 6⋅3 1177 (7⋅0) 5⋅9
Cancer 1111 (9⋅9) 3⋅5 538 (9⋅7) 4⋅6 1649 (9⋅8) 3⋅9
Cirrhosis 84 (0⋅7) 5 39 (0⋅7) 10 123 (0⋅7) 6⋅5
Congestive cardiac failure 177 (1⋅6) 11⋅39 9 ( 1 ⋅8) 9 276 (1⋅6) 10⋅5
Smoker 1106 (9⋅9) 0⋅9 583 (10⋅5) 1⋅7 1689 (10⋅1) 1⋅2
Diabetes (insulin-dependent) 303 (2⋅7) 3⋅3 142 (2⋅5) 2⋅1 445 (2⋅7) 2⋅9
Diabetes (non-insulin-dependent) 718 (6⋅4) 2⋅8 410 (7⋅4) 2⋅7 1128 (6⋅7) 2⋅7
Ischaemic heart disease 1079 (9⋅6) 3⋅0 556 (10⋅0) 5⋅0 1635 (9⋅7) 3⋅7
Respiratory disease 1362 (12⋅1) 3⋅5 720 (12⋅9) 4⋅3 2082 (12⋅4) 3⋅7
TIA/stroke 468 (4⋅2) 5⋅3 209 (3⋅8) 4⋅8 677 (4⋅0) 5⋅2
Values in parentheses are percentages. ASA-PS, American Society of Anesthesiologists Physical Status; Xmajor, extra major; TIA, transient ischaemic
attack.
was used to construct a model to predict 30-day mortal-
ity in the derivation cohort. All variables that were sig-
nificant on univariable analysis at P <0⋅100 were entered
into the initial model. Age was treated as a categorical vari-
able, with cut-offs at 65 and 80years, based on inspection
of a locally weighted scatter plot curve. All co-morbidity
variables were included as indicator variables. High-risk
surgical specialty was included as a binary indicator vari-
able, with vascular, gastrointestinal and thoracic surgery
defined as the high-risk specialties26. In addition, inter-
actions between each co-morbidity and each age category
were tested, with each of three ASA-PS categories: high
(ASA-PS IV or V), medium (III) or low (I or II). The
interaction between cancer and the expedited surgery
category was also tested. Variables were dropped from the
model sequentially on repeated regression analyses, ini-
tially at P >0⋅100, and then P >0⋅050.
The final restricted model constructed from the deriva-
tion cohort was then tested on the validation cohort. A
risk score was derived for each patient by summating the
model coefficients for risk factors present. This was then
converted into a percentage risk using the formula:
ln(R∕(1−R)) = constant + risk score
where R is the risk of 30-day mortality, and the constant
was derived from the logistic regression model.
The accuracy of this novel risk stratification tool, the
Surgical Outcome Risk Tool (SORT), was then assessed
in the validation cohort by calculating the area under
the receiver operating characteristic curve (AUROC) to
measure discrimination and using the Hosmer–Lemeshow
test to assess calibration. The AUROC has a value between
0⋅5a n d1 ⋅0, where 0⋅5 is equivalent to guessing, and 1⋅0
indicates perfect predictive accuracy. Previous work has
described an AUROC of less than 0⋅7 to indicate poor
performance, 0⋅7–0⋅9 to indicate moderate performance,
and over 0⋅9 to indicate high performance23,28.T h e
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Table 3 Specialty case mix in the derivation and validation
cohorts
No. of patients
Derivation Validation Total
Abdominal (bariatric) 46 28 74
Abdominal (endocrine) 4 0 4
Abdominal (gastrointestinal) 1802 864 2666
Abdominal (hepatobiliary) 440 222 662
Body surface (breast) 561 274 835
Body surface (other) 389 200 589
Endocrine 142 72 214
Gynaecology 1164 594 1758
Head and neck 848 409 1257
Ophthalmology 126 73 199
Orthopaedics 3945 1958 5903
Thoracic 120 71 191
Urology 1135 569 1704
Vascular 497 235 732
Total 11219 5569 16788
Hosmer–Lemeshow test compares observed and pre-
dicted event rates across a range of predicted risk. A
non-significant test result indicates that a model is well
calibrated.
Finally, χ2 testing was used to compare the accuracy of
the SORT (as measured by AUROC) and two previously
published risk stratification tools: ASA-PS19 and a mod-
ified version of the SRS (with the 4 classes of surgi-
cal severity described above, rather than 5 as originally
defined)20. The calibration of the SRS was tested using the
Hosmer–Lemeshow test.
All data were analysed using Microsoft® Excel 2010
(Microsoft, Redmond, Washington, USA) and Stata®
InterCooled 12 (StataCorp LP, College Station, Texas,
USA). An app and web-based calculator were developed to
facilitate risk calculation at the bedside.
Results
A total of 19097 case report forms were collected from 326
hospitals (Fig. 1). Characteristics of the 916 patients whose
mortality data were unobtainable were similar to those of
thefinalsampleusedintheanalysis(Table 1).Themortality
rate was lower among the 2047 patients who were excluded
owing to missing data (Fig. 1) than in the included patients
(0⋅6 versus 1⋅4 per cent; P =0⋅003). After exclusions, the
sample size for analysis was 16788, of which the derivation
cohort comprised 11219 patients and the validation cohort
5569. Descriptive data for these cohorts are summarized
in Tables2 and 3. Comparison of the surgical severity of
510 different surgical procedures in the AXA and BUPA
schedules encompassed 5903 orthopaedic and 2666 gastro-
intestinal surgical procedures. Only 18 procedures (3⋅5
per cent) were coded differently, and in all instances the
difference in grading was between consecutive categories.
Model development and derivation
Creatinine and haemoglobin results were excluded from
analyses because of the large proportion of missing
data (27⋅2a n d2 8 ⋅3 per cent respectively). Neither sex
nor smoking history was associated significantly with
30-day mortality on univariable analysis, and so these
were excluded from the multivariable analysis. Forty-five
variables were included in the initial model (Table S1, sup-
porting information). Stepwise sequential analyses based
on significance testing led to a final model of six variables
Table 4 Restricted model of six variables following the analyses
Coefficient Standard error 95% c.i. zP
ASA-PS grade
III 1⋅411 0⋅248 0⋅925, 1⋅900 5⋅69 <0⋅001
IV 2⋅388 0⋅290 1⋅821, 2⋅956 8⋅25 <0⋅001
V4 ⋅081 0⋅596 2⋅911, 5⋅251 6⋅84 <0⋅001
Urgency of surgery
Expedited 1⋅236 0⋅296 0⋅657, 1⋅812 4⋅18 <0⋅001
Urgent 1⋅657 0⋅259 1⋅149, 2⋅164 6⋅40 <0⋅001
Immediate 2⋅452 0⋅410 1⋅649, 3⋅256 5⋅98 <0⋅001
Specialty
High-risk specialty (gastrointestinal, thoracic or vascular) 0⋅712 0⋅188 0⋅344, 1⋅081 3⋅79 <0⋅001
Severity of surgery
Xmajor/complex 0⋅381 0⋅185 0⋅019, 0⋅744 2⋅06 0⋅039
Cancer 0⋅667 0⋅211 0⋅253, 1⋅081 3⋅16 0⋅002
Age (years)
65–79 0⋅777 0⋅258 0⋅272, 1⋅281 3⋅02 0⋅003
≥80 1⋅591 0⋅260 1⋅082, 2⋅010 6⋅12 <0⋅001
ASA-PS, American Society of Anesthesiologists Physical Status; Xmajor, extra major.
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that were independent predictors of 30-day mortality
(Table 4).
The model coefficients were then used to develop a
formula for a risk score as follows, where each variable is
assigned a value of 1 if present and 0 if absent:
Risk score = (ASA − PS III × 1.411)
+ (ASA − PS IV × 2.388)
+ (ASA − PS V × 4.081)
+
(
urgency ‘expedited’ × 1.236
)
+
(
urgency ‘urgent’ × 1.657
)
+
(
urgency ‘immediate’ × 2.452
)
+
(
high-risk specialty × 0.712
)
+
(
severity ‘Xmajor complex’ × 0.381
)
+ (cancer × 0.667)
+
(
age 65–79 years × 0.777
)
+
(
age ≥ 80 years × 1.591
)
This score was then converted into a percentage risk of
30-day mortality using the formula described in the meth-
ods, with a constant of −7⋅366.
When these calculations were used to produce a
percentage predicted mortality for each patient in the
validation cohort, the AUROC for 30-day mortality was
0⋅91, indicating high discrimination. The P value for the
Hosmer–Lemeshow χ2 test was 0⋅204, indicating that the
new model was well calibrated in the validation cohort.
Observed and predicted mortality rates for the SORT are
shown in Fig. 2 and Table 5.
The discrimination of the SORT was also tested in
seven surgical specialty subgroups for which there were at
least 100 patients and at least one death in the validation
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Fig. 2 Observed versus predicted 30-day mortality at varying
levels of risk in the validation cohort of 5569 patients undergoing
non-cardiac surgery. Circle size corresponds to the proportion of
patients at each level of risk
cohort, to enable AUROC curves to be calculated (Table 6).
Discrimination in these subgroups varied between moder-
ate (AUROC 0⋅82 for hepatobiliary surgery) and excellent
(AUROC 0⋅96 for head and neck surgery).
Comparison with previously validated risk
stratification tools
Both the ASA-PS and the SRS demonstrated moderately
good discrimination when tested in the validation cohort:
AUROC 0⋅87 (95 per cent c.i. 0⋅84 to 0⋅91) and 0⋅88
(0⋅84 to 0⋅92) respectively. However, the SORT was sig-
nificantly more accurate, with an AUROC of 0⋅91 (0⋅88 to
0⋅94) (P <0⋅001) (Fig. 3). Furthermore, the SRS was poorly
calibrated (P <0⋅001, Hosmer–Lemeshow χ2 test). Exam-
ination of observed:predicted ratios at different levels of
riskdemonstratedthattheSRSoverestimatedriskinallbut
the highest-risk patients.
Table 5 Observed versus predicted mortality in validation cohort in nine quantiles, with Hosmer–Lemeshow statistic
Quantile
No. of
patients
Mean SORT estimated
probability of death (%)
Observed deaths
at 30days
Predicted deaths
at 30days
Hosmer–Lemeshow
statistic
1 1220 0⋅063 0 (0) 0⋅8( 0 ⋅1) 0⋅77
2 496 0⋅093 0 (0) 0⋅5( 0 ⋅1) 0⋅46
3 523 0⋅134 2 (0⋅4) 0⋅7( 0 ⋅1) 2⋅41
4 572 0⋅206 1 (0⋅2) 1⋅2( 0 ⋅2) 0⋅03
5 617 0⋅309 2 (0⋅3) 1⋅9( 0 ⋅3) 0⋅00
6 510 0⋅463 5 (1⋅0) 2⋅4( 0 ⋅5) 2⋅96
7 527 0⋅723 1 (0⋅2) 3⋅8( 0 ⋅7) 2⋅09
8 561 1⋅595 12 (2⋅1) 8⋅9( 1 ⋅6) 1⋅07
9 543 9⋅818 64 (11⋅8) 53⋅3( 9 ⋅8) 2⋅37
Total 5569 1⋅319 87 (1⋅6) 73⋅4( 1 ⋅3) 12⋅16
Values in parentheses are percentages. Nine quantiles were used (rather than 10) because of ties within groups. SORT, Surgical Outcome Risk Tool.
χ2 =12⋅16, P =0⋅204.
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Table 6 Area under the receiver operating characteristic (ROC)
curves for surgical subspecialty groups
No. of patients
in validation cohort AUROC of SORT
Orthopaedics 1958 0⋅93
Gastrointestinal 864 0⋅88
Urology 569 0⋅95
Head and neck 409 0⋅96
Vascular 235 0⋅84
Hepatobiliary 222 0⋅82
Body surface (other) 200 0⋅87
AUROC, area under the receiver operating characteristic curve; SORT,
Surgical Outcome Risk Tool.
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Fig. 3 Receiver operating characteristic (ROC) curves for the
Surgical Outcome Risk Tool (SORT), American Society of
Anesthesiologists Physical Status (ASA-PS) grade and Surgical
Risk Scale (SRS) for the validation cohort of 5569 patients
undergoing non-cardiac surgery. The areas under the ROC
curves were 0⋅91 (95 per cent c.i. 0⋅88 to 0⋅94), 0⋅87 (0⋅84 to
0⋅91) and 0⋅88 (0⋅84 to 0⋅92) respectively
Discussion
A novel risk stratification tool comprising six preoperative
variables was developed and validated internally to pre-
dict 30-day mortality in adults undergoing non-cardiac
non-neurological inpatient surgery. Internal validation
demonstrated the SORT to be more accurate than the
ASA-PS and the SRS. There remain barriers to the rou-
tine use of risk stratification, including extensive data
collection and data entry, the use of intraoperative and
postoperative variables, and the inability to calculate an
individual percentage mortality risk. By addressing these
issues in this model, and developing an app and web-based
calculator, the SORT has the potential to become used
more widely. Although developed as a risk prediction tool
before surgery, the SORT may also be valid as a risk adjust-
ment tool in post hoc analyses of clinical performance, and
thus aid epidemiological research and comparative audit.
All the variables in the SORT are known predictors of
adverse outcome after surgery21,26,29–33. Surgical sever-
ity is a significant contributor to postoperative mortal-
ity risk. The AXA-PPP system is an objective and widely
used measure of operative severity, which employs the
same classification method (Clinical Coding and Sched-
ule Development group), and is very similar to the BUPA
schedule used in the SRS20. Although both have their limi-
tations, an objective method of defining surgical severity is
likely to reduce inter-rater variability and should therefore
improve the accuracy of the SORT in clinical practice.
Some variables previously associated with risk of surgical
mortality,suchasraisedbodymassindex,lowhaemoglobin
and raised creatinine level34–37, were omitted from the
analyses owing to poor data collection rates during the ini-
tialstudy.FortheSORTtobeusedroutinely,thespeedand
simplicityofcollectingvariableswereimportantfeaturesto
retain. Therefore, a choice was made not to use imputation
to derive missing data. The SORT demonstrated high per-
formance (AUROC over 0⋅9) in internal validation, so the
inclusion of other variables is likely to have had only a min-
imal impact on performance, at the risk of making the tool
lesseasytouse.Includingalargernumberofvariables,such
as described previously38, would greatly increase the time
taken to collect data, and thereby decrease the usability of
the tool. The inclusion of haematological and biochemi-
cal variables would have prevented the SORT being used
whenbloodresultswerenotavailable.Withrespecttobody
massindex,thereisevidencethatothermeasurementssuch
as waist–hip ratio, waist-to-height ratio and waist circum-
ference are better predictors of risk39,40.
One co-morbidity that did not reach significance in the
final model, despite being highly predictive of mortality
on univariable analysis, was congestive cardiac failure. This
may seem surprising given the known association between
cardiac failure and outcome in surgical patients. Adjust-
ment for ASA-PS grade, which is a reflection of functional
capacity, is likely to explain this finding.
Systematic review23 has previously identified P-POS-
SUM and SRS as the most accurate methods of periop-
erative risk stratification in heterogeneous cohorts23. Even
though P-POSSUM has been validated multiply, it is still
not used widely. The SORT has a number of advan-
tages. First, it is a parsimonious model, consisting of only
six preoperative variables, compared with 18 preoperative,
intraoperativeandpostoperativevariablesforP-POSSUM.
Second, POSSUM was originally designed as a post hoc
audit tool. When risk assessment is arguably the most
important (in the preoperative assessment clinic or emer-
gency department), many variables required to compute
the preoperative part of P-POSSUM (for example blood
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results) may not be available. Furthermore, P-POSSUM
contains subjective variables, such as interpretation of a
chest radiograph, and potential interobserver variability
may affect its accuracy.
Conversely, the population-based ASA-PS is a widely
used measure of perioperative risk, and has face validity as
a measure of functional capacity. Although it was demon-
strated to be a moderately accurate predictor of outcome in
thepresentanalysis,atleastfourpreviousstudiesfoundthat
it lacked accuracy when tested in heterogeneous cohorts23.
The lack of discrimination between patients in ASA-PS
grade III is a particular limitation. A cut-off of 10 per cent
predictedshort-termmortalityriskhasbeenrecommended
when considering strategies to improve perioperative care
and outcome, including planned critical care admission41.
The population mortality of patients with ASA-PS grade
III in this study was 3⋅2 per cent, and that of the ASA-PS
grade IV population was 16⋅5 per cent; these findings are
broadly consistent with other studies30. Thus there is a
need to be able to discriminate between patients in the
ASA-PS grade III population, which can be achieved only
by using a tool with more variables.
The SRS was also designed as a risk adjustment tool
for comparative audit. Although it has been identified as
a promising alternative to more complex risk stratifica-
tion tools23, previous validation studies are limited to two
analyses from the same collaborators20,33, and a subsequent
external validation that included only urgent or emergency
surgery in a single hospital42. The analysis undertaken in
thepresentstudydemonstratedthattheSRSoverestimated
risk in all but the highest-risk patients.
Encouraging the widespread and routine use of risk pre-
diction tools is a challenge. Ease of use and face validity are
two important factors that may influence this, and which
have been addressed for the SORT. With easily available
preoperative data, and an app or web-based calculator, it
is hoped that adoption of the SORT may exceed that of
other models.
The present study has strengths and some weaknesses.
It is the largest study validating risk stratification tools
prospectively in a heterogeneous cohort of patients under-
going non-cardiac surgery in the UK23. Despite the large
sample size, some selection bias may have occurred as the
data capture did not encompass all patients undergoing
surgery in the study week. Furthermore, it was not possible
to determine whether 4⋅9 per cent of patients who met the
inclusion criteria were dead or alive, despite linkage with
national databases. In all instances, this was because key
demographicinformationrequiredfordatalinkage(suchas
NHS number) was missing. Despite these limitations, the
sample analysed was representative, and had face validity,
as the prevalence of co-morbid risk factors and 30-day
mortality statistics were broadly similar to those reported
previously32,43. The results are generalizable owing to the
broadrepresentationofsizeandtypesofhospital,theinclu-
sion of surgery of all urgencies, and a wide range of special-
ties for inpatient surgery in England, Wales and Northern
Ireland. The generalizability of the model in international
cohorts remains unknown.
The SORT could be used in conjunction with clinical
judgement to aid decision-making and facilitate informed
consent. External validation of the SORT is necessary
to test its validity further, as is the periodic recalibra-
tion and re-evaluation of the model to maintain validity
as healthcare delivery changes44,45. Studies evaluating the
impact of risk stratification on improving patient outcomes
through individual care planning should be a research
priority as there is an opportunity to improve outcomes
substantially14,43,46,47.
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